Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis Source: ERJ Open Res, 5 (4) 00051-2019; 10.1183/23120541.00051-2019 Year: 2019
Cystic fibrosis: Achromobacter xylosoxidans colonized patients have more severe respiratory disease Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013
Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevanceSource: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005
Bacterial infection and lung function in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 615s Year: 2005
Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections Source: Eur Respir J 2012; 40: 227-238 Year: 2012
Burkholderia cepacia infection in adult cystic fibrosis patients: Its impact on lung function and survival Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010
Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017 Year: 2017
DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003
The identification of bacterial strains in specimens of adult cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 49s Year: 2004
LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006
The spectrum of Nocardia lung disease in cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015
Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008
Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients Source: Eur Respir J 2004; 23: 851-856 Year: 2004
Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis Source: ERJ Open Res, 4 (2) 00162-2017; 10.1183/23120541.00162-2017 Year: 2018
Screening for cystic fibrosis among high risk group patients with chronic lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002
Achromobacter xylosoxidans strains with shared genotype among patients attending a cystic fibrosis (CF) rehabilitation centreSource: Eur Respir J 2005; 26: Suppl. 49, 596s Year: 2005
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018